Where does Max Delbrück-Centrum Für Molekulare Medizin rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Max Delbrück-Centrum Für Molekulare Medizin ranks #24,768 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Max Delbrück-Centrum Für Molekulare Medizin hold?

Max Delbrück-Centrum Für Molekulare Medizin holds 11 US utility patents granted between 2015 and 2025, spanning 7 technology areas.

What is Max Delbrück-Centrum Für Molekulare Medizin's Innovation Score?

Max Delbrück-Centrum Für Molekulare Medizin has an Innovation Score of 27.7 out of 100 (25th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Max Delbrück-Centrum Für Molekulare Medizin's patent grant rate increasing or decreasing?

Max Delbrück-Centrum Für Molekulare Medizin's recent grant velocity is +0% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Max Delbrück-Centrum Für Molekulare Medizin's patents?

Max Delbrück-Centrum Für Molekulare Medizin's patents average 14.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Max Delbrück-Centrum Für Molekulare Medizin

Q: What technology areas does Max Delbrück-Centrum Für Molekulare Medizin focus on?

Max Delbrück-Centrum Für Molekulare Medizin's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 7 patents, ranking #2,588 of 6,058 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Q: How is the Max Delbrück-Centrum Für Molekulare Medizin patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 11 granted patents across 7 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Max ranks #24,768 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 7 technology areas.

#24,768
of 49,997 US assignees by volume: 25th percentile
by Innovation Score (27.7/100): 14.1
avg claims per patent: +0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R24768 · Foreign Corporation #24,768 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

GRANTS-MICRO 11 grants
MID-PACK #24,768/49,997
PHOTO-FINISH Masterwork Automodul…
CPC-NARROW A61P · 7 areas
INNOV-THIN 27.7/100
CLAIMS-RICH 14.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-FLAT +0% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Masterwork Automodules Tech Corp. Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Max’s 27.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.6 pts (31%) Velocity 1.3 pts (5%) Breadth 9.4 pts (34%) Claim depth 8.5 pts (31%)

Qualcomm Incorporated · highest

85
Max Delbrück-Centrum… · this assignee

28
3D Lighting… · lowest

7

What this shows Max's Innovation Score is 27.7/100 (25th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Max?

Each dot is one of Max’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Max’s own 14.1 claims/patent is at or below the 14.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Max vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Max's grants concentrate

Max Delbrück-Centrum Für Molekulare Medizin is a focused PatentsView assignee: 7 CPC subclasses with 63.6% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2015. By volume, Max sits between Masterwork Automodules Tech Corp. Ltd and Medical Specialties, Inc..

Max's three-year grant acceleration

Max Delbrück-Centrum Für Molekulare Medizin shows 1 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Masterwork Automo…

11
Mate Precision To…

11
Mavagail Technolo…

11
Maverick Industri…

11
Maxion Wheels Ger…

11
Maxitrol

11
Med-genesis

11
Medical Specialti…

11
Max Delbrück-cent… ◀

11

What this shows Max holds 11 patents at rank #24,795, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Max

By rank, the assignees closest to #24,795 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Max's primary technology class.

Max's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 25th percentile higher than 25% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Max Delbrück-Centrum Für Molekulare Medizin patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	9.1%
2016	2	18.2%
2017	1	9.1%
2019	1	9.1%
2020	2	18.2%
2021	2	18.2%
2023	1	9.1%
2025partial year	1	9.1%

Which technologies does Max Delbrück-Centrum Für Molekulare Medizin patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 7

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 7

C07D - Heterocyclic Compounds 5

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 3

C12Y - Enzymes 3

C07K - Peptides 2

C07C - Acyclic OR Carbocyclic Compounds 2

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Max Delbrück-Centrum Für Molekulare Medizin's patent record in context - here's where to go next.

Max Delbrück-Centrum Für Molekulare Medizin's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 63.6% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #24,768 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Max Delbrück-Centrum Für Molekulare Medizin against Masterwork Automodules Tech Corp. Ltd, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 27.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.